

TRIAL RESULTS – 13th OCTOBER 2021`

[Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China](#)

“We are pleased to see that the results of our bridging study are consistent with those of the SOPHIA trial that were the basis for the approval of Margenza® in the United States,” said Alan Sandler, M.D., President and Head of Global Development, Oncology. “Both trials support the potential use of margetuximab as another treatment option for a very difficult-to-treat patient population. The successful completion of our bridging study further demonstrates Zai Lab’s capabilities to produce clinical data of global quality to support regulatory approval in China in collaboration with our partners.”

[Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ \(Trilaciclib\) Reduced Use of Supportive Care Interventions in ES-SCLC Patients Who Receive the Drug Prior to Chemotherapy](#)

“The results from our analysis show clear myeloprotection benefits associated with the administration of trilaciclib prior to chemotherapy in patients with ES-SCLC,” said Renata Ferrarotto, MD, Associate Professor, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center and lead author of the study. “By reducing the need for associated supportive care, trilaciclib has the potential to reduce both the societal and economic burden of chemotherapy-induced myelosuppression.”

[ATA 2021: Updated Vitrakvi® \(larotrectinib\) Sub-Analysis Supports Efficacy and Safety in Adult and Pediatric TRK Fusion Thyroid Cancer Patients](#)

“Being one of the more common solid tumors, thyroid cancer – specifically papillary thyroid cancer – has one of the highest NTRK fusion prevalence rates of up to 25%,³ especially in younger patients,” said Steven G. Waguespack, M.D., Professor of Endocrine Neoplasia and Hormonal Disorders at The University of Texas MD Anderson Cancer Center. “In patients with thyroid cancer who harbor an NTRK gene fusion and who require systemic therapy for advanced disease, these data support larotrectinib’s potential as an appropriate treatment option.”